Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease

mTOR Signaling in Growth, Metabolism, and Disease

Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555 · see citing works

Causal analysis approaches in Ingenuity Pathway Analysis

Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724 · see citing works

Revised response criteria for malignant lymphoma.

Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537 · see citing works

The PI3K Pathway in Human Disease

Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749 · see citing works

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., d'Agay, M., Clauvel, J., Raphael, M., Degos, L., et al. (1995) · Blood · doi:10.1182/blood.v86.4.1276.bloodjournal8641276 · Cited by 2,296 · see citing works

Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery

Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754 · see citing works

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

Guba, M. O., von Breitenbuch, P., Steinbauer, M. G. M., Koehl, G. E., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S. A., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739 · see citing works

Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin

Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186 · see citing works

Efficacy and safety of sirolimus in lymphangioleiomyomatosis

McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099 · see citing works

Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks

Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015 · see citing works

Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease

Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928 · cited 1× · see citing works

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754 · see citing works

International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Fajgenbaum, D., Uldrick, T., Bagg, A., Frank, D. M., Wu, D., Srkalović, G., Simpson, D., Liu, A. Y., Menke, D., Chandrakasan, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-746933 · Cited by 601 · see citing works

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

van Rhee, F., Wong, R. S., Munshi, N., Rossi, J.-F., Ke, X.-Y., Fosså, A., Simpson, D., Capra, M., Liu, T., Hsieh, R. K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70319-5 · Cited by 454 · see citing works

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial

Lai, Z.-W., Kelly, R., Winans, T., Marchena, I., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Tily, H., Francis, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30485-9 · Cited by 412 · see citing works

Kaposi's Sarcoma-Associated Herpesvirus

Boshoff, C., & Weiss, R. A. (1998) · Advances in cancer research · doi:10.1016/s0065-230x(08)60739-3 · Cited by 398 · see citing works

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Rhee, F. V., Voorhees, P., Dispenzieri, A., Fosså, A., Srkalović, G., Ide, M., Munshi, N., Schey, S., Streetly, M., Pierson, S., et al. (2018) · Blood · doi:10.1182/blood-2018-07-862334 · Cited by 387 · see citing works

Idiopathic multicentric Castleman's disease: a systematic literature review

Liu, A. Y., Nabel, C. S., Finkelman, B. S., Ruth, J. R., Kurzrock, R., van Rhee, F., Krymskaya, V. P., Kelleher, D. P., Rubenstein, A. H., & Fajgenbaum, D. C. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00006-5 · Cited by 331 · see citing works

Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody

Beck, J. T., Hsu, S.-M., Wijdenes, J., Bataille, R., Klein, B., Vesole, D. H., Hayden, K., Jagannath, S., & Barlogie, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300904 · Cited by 322 · see citing works

Production of Vascular Endothelial Growth Factor by Murine Macrophages

Xiong, M., Elson, G., Legarda, D., & Leibovich, S. J. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65601-5 · Cited by 306 · see citing works

The Clinical Spectrum of Castleman's Disease

Dispenzieri, A., Armitage, J., Loe, M. J., Geyer, S. M., Allred, J., Camoriano, J. K., Menke, D. M., Weisenburger, D., Ristow, K. M., Dogan, A., et al. (2012) · American journal of hematology/oncology · doi:10.1002/ajh.23291 · Cited by 244 · see citing works

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

van Rhee, F., Fayad, L., Voorhees, P. M., Furman, R. R., Lonial, S., Borghaei, H., Sokol, L., Crawford, J. H., Cornfeld, M. J., Qi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2377 · Cited by 244 · see citing works

Pathological Findings in Human Autoimmune Lymphoproliferative Syndrome

Lim, M. S., Straus, S. E., Dale, J. K., Fleisher, T. A., Stetler‐Stevenson, M., Strober, W., Sneller, M. C., Puck, J. M., Lenardo, M. J., Elenitoba‐Johnson, K. S. J., et al. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65742-2 · Cited by 221 · see citing works

mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging

Perl, A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12756 · Cited by 218 · see citing works

Castleman-Kojima Disease (TAFRO Syndrome) : A Novel Systemic Inflammatory Disease Characterized by a Constellation of Symptoms, Namely, Thrombocytopenia, Ascites (Anasarca), Microcytic Anemia, Myelofibrosis, Renal Dysfunction, and Organomegaly : A Status Report and Summary of Fukushima (6 June, 2012) and Nagoya Meetings (22 September, 2012)

Kawabata, H., Takai, K., Kojima, M., Nakamura, N., Aoki, S., Nakamura, S., Kinoshita, T., & Masaki, Y. (2013) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.53.57 · Cited by 189 · see citing works

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome

Teachey, D. T., Greiner, R. J., Seif, A. E., Attiyeh, E. F., Bleesing, J., Choi, J. K., Manno, C. S., Rappaport, E. F., Schwabe, D., Sheen, C., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07595.x · Cited by 171 · see citing works

Use of a claims database to characterize and estimate the incidence rate for Castleman disease

Munshi, N. C., Mehra, M., de Velde, H. J. V., Desai, A. G., Potluri, R. C., & VERMEULEN, J. T. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.953145 · Cited by 170 · see citing works

Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?

Nagelkerke, S. Q., & Kuijpers, T. W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00674 · Cited by 140 · see citing works

Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome

Völkl, S., Rensing‐Ehl, A., Allgäuer, A., Schreiner, E., Lorenz, M. R., Rohr, J., Klemann, C., Fuchs, I., Schuster, V. H., von Bueren, A. O., et al. (2016) · Blood · doi:10.1182/blood-2015-11-685024 · Cited by 98 · see citing works

Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (Anti-IL6 Monoclonal Antibody) in patients with multicentric castleman disease

Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., Bandekar, R., Hall, B., van de Velde, H., Vermeulen, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0134 · Cited by 97 · see citing works

Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease

Pierson, S. K., Stonestrom, A. J., Shilling, D., Ruth, J., Nabel, C. S., Singh, A., Ren, Y., Stone, K., Li, H., van Rhee, F., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25123 · Cited by 90 · see citing works

Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome

Iwaki, N., Gion, Y., Kondo, E., Kawano, M., Masunari, T., Moro, H., Nikkuni, K., Takai, K., Hagihara, M., Hashimoto, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep42316 · Cited by 67 · see citing works

Eruptive Cherry Hemangiomatosis Associated With Multicentric Castleman Disease

Fajgenbaum, D. C., Rosenbach, M. A., van Rhee, F., Nasir, A., & Reutter, J. C. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.1552 · Cited by 51 · see citing works

Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T‐cell receptor Vβ repertoire

Battaglia, A., Ferrandina, G., Buzzonetti, A., Malinconico, P., Legge, F., Salutari, V., Scambia, G., & Fattorossi, A. (2003) · Immunology · doi:10.1046/j.1365-2567.2003.01742.x · Cited by 49 · see citing works

Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease

Nabel, C. S., Sameroff, S. C., Shilling, D. J., Alapat, D. V., Ruth, J. R., Kawano, M., Sato, Y., Stone, K., Spetalen, S., Valdivieso, F., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218660 · Cited by 45 · see citing works

Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients

Pavón, E. J., Zumaquero, E., Rosal‐Vela, A., Khoo, K. M., Cerezo‐Wallis, D., García‐Rodríguez, S., Carrascal, M., Abián, J., Graeff, R. M., Callejas-Rubio, J. L., et al. (2013) · Cytokine · doi:10.1016/j.cyto.2013.02.023 · Cited by 44 · see citing works

Rapamycin: In Vitro Profile of a New Immunosuppressive Macrolide.

Sehgal, S. N., & Bansbach, C. C. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb35852.x · Cited by 44 · see citing works

Effect of rapamycin on the cyclosporin A–resistant CD28-mediated costimulatory pathway

Ghosh, P., Buchholz, M. A., Yano, S., Taub, D. D., & Longo, D. L. (2002) · Blood · doi:10.1182/blood-2001-11-0062 · Cited by 39 · see citing works

Antitumoral Activity of Rapamycin Mediated Through Inhibition of HIF-1alpha and VEGF in Hepatocellular Carcinoma

Wang, W., Jia, W., Xu, G., Wang, Z.-H., Li, J., Ma, J., Ge, Y., Xie, S., & Yu, J.-H. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0605-3 · Cited by 38 · see citing works

Mechanistic Target of Rapamycin Complex 1/S6 Kinase 1 Signals Influence T Cell Activation Independently of Ribosomal Protein S6 Phosphorylation

Salmond, R. J., Brownlie, R. J., Meyuhas, O., & Zamoyska, R. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501473 · Cited by 32 · see citing works

Rapamycin Inhibits VEGF-Induced Microvascular HyperpermeabilityIn Vivo

Kim, D. D., Kleinman, D. M., Kanetaka, T., Gerritsen, M. E., Nivaggioli, T., Weber, D. S., & Durán, W. N. (2010) · Microcirculation · doi:10.1111/j.1549-8719.2009.00012.x · Cited by 20 · see citing works

Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.

Beran, O., Holub, M., Spála, J., Kalanin, J., & Stankova, M. (2003) · PubMed · Cited by 16 · see citing works

Sirolimus-Based Immunosuppressive Regimens in Renal Transplantation: A Systemic Review

Zhao, D., Li, S. W., & Sun, Q. (2016) · Transplantation Proceedings · doi:10.1016/j.transproceed.2016.01.002 · Cited by 16 · see citing works

Multiplexed protein profiling after aneurysmal subarachnoid hemorrhage: Characterization of differential expression patterns in cerebral vasospasm

Walcott, B. P., Patel, A. P., Stapleton, C. J., Trivedi, R. A., Young, A. M. H., & Ogilvy, C. S. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.06.004 · Cited by 6 · see citing works

Cytokine storm

Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196 · see citing works

The next generation of evidence-based medicine

Subbiah, V. (2023) · Nature Medicine · doi:10.1038/s41591-022-02160-z · Cited by 570 · see citing works

Overview of Castleman disease

Dispenzieri, A., & Fajgenbaum, D. C. (2020) · Blood · doi:10.1182/blood.2019000931 · Cited by 487 · see citing works

Castleman disease

Carbone, A., Borok, M. Z., Damania, B., Gloghini, A., Polizzotto, M. N., Jayanthan, R., Fajgenbaum, D. C., & Bower, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00317-7 · Cited by 214 · see citing works

Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p

Shao, M., Xu, Q., Wu, Z., Chen, Y., Shu, Y., Cao, X., Chen, M., Zhang, B., Zhou, Y., Yao, R., et al. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-1550-0 · Cited by 200 · see citing works

Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes

England, J. T., Abdulla, A., Biggs, C. M., Lee, A. Y. Y., Hay, K. A., Hoiland, R. L., Wellington, C. L., Sekhon, M. S., Jamal, S., Shojania, K., et al. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100707 · Cited by 178 · see citing works

Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine

Ibrahim, H., Perl, A., Smith, D. E., Lewis, T. C., Kon, Z. N., Goldenberg, R., Yarta, K., Staniloae, C. S., & Williams, M. R. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108544 · Cited by 146 · see citing works

Diabetic ferroptosis plays an important role in triggering on inflammation in diabetic wound

Li, S., Li, Y., Wu, Z., Wu, Z., & Fang, H. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00042.2021 · Cited by 117 · see citing works

Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate

Mehta, P., & Fajgenbaum, D. C. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000822 · Cited by 90 · see citing works

Increased mTOR activation in idiopathic multicentric Castleman disease

Arenas, D. J., Floess, K., Kobrin, D., Pai, R.-A. L., Srkalovic, M. B., Tamakloe, M.-A., Rasheed, R., Ziglar, J., Khor, J., Parente, S. A. T., et al. (2020) · Blood · doi:10.1182/blood.2019002792 · Cited by 83 · see citing works

Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease

Pai, R.-A. L., Japp, A. S., Gonzalez, M., Rasheed, R. F., Okumura, M., Arenas, D., Pierson, S. K., Powers, V., Layman, A. A. K., Kao, C., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135031 · Cited by 68 · see citing works

Hypoxia preconditioning of adipose stem cell-derived exosomes loaded in gelatin methacryloyl (GelMA) promote type H angiogenesis and osteoporotic fracture repair

Li, X., Fang, S., Wang, S., Xie, Y., Xia, Y., Wang, P., Hao, Z., Xu, S., & Zhang, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02342-6 · Cited by 65 · see citing works

Drug Regulation in the Era of Individualized Therapies

Woodcock, J., & Marks, P. W. (2019) · New England Journal of Medicine · doi:10.1056/nejme1911295 · Cited by 65 · see citing works

The complex network of mTOR signaling in the heart.

Sciarretta, S., Forte, M., Frati, G., & Sadoshima, J. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab033 · Cited by 58 · see citing works

Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease

Nishikori, A., Nishimura, M. F., Nishimura, Y., Otsuka, F., Maehama, K., Ohsawa, K., Momose, S., Nakamura, N., & Sato, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810301 · Cited by 54 · see citing works

Artificial apoptotic cells/VEGF-loaded injectable hydrogel united with immunomodification and revascularization functions to reduce cardiac remodeling after myocardial infarction

Zhang, X., Lyu, Y., Liu, Y., Yang, R., Liu, B., Li, J., Xu, Z., Zhang, Q., Yang, J., & Liu, W. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101227 · Cited by 49 · see citing works

Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.

Pierson, S., Shenoy, S. A., Oromendia, A., Gorzewski, A., Pai, R., Nabel, C., Ruth, J., Parente, S. A. T., Arenas, D. J., Guilfoyle, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004016 · Cited by 45 · see citing works

Colchicine improves severe acute pancreatitis-induced acute lung injury by suppressing inflammation, apoptosis and oxidative stress in rats

Zhang, D., Li, L., Li­, ­., Wei, Y., Tang, J., Man, X., & Liu, F. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113461 · Cited by 44 · see citing works

Individualized therapy trials: navigating patient care, research goals and ethics

Kane, P. B., Bittlinger, M., & Kimmelman, J. (2021) · Nature Medicine · doi:10.1038/s41591-021-01519-y · Cited by 44 · see citing works

Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan

Fujimoto, S., Kawabata, H., Sakai, T., Yanagisawa, H., Nishikori, M., Nara, K., Ohara, S., Tsukamoto, N., Kurose, N., Yamada, S., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-03008-3 · Cited by 42 · see citing works

Pathogens MenTORing Macrophages and Dendritic Cells: Manipulation of mTOR and Cellular Metabolism to Promote Immune Escape

Nouwen, L. V., & Everts, B. (2020) · Cells · doi:10.3390/cells9010161 · Cited by 42 · see citing works

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Chen, L. Y. C., Zhang, L., & Fajgenbaum, D. C. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43269 · Cited by 40 · see citing works

Therapeutic mTOR blockade in systemic autoimmunity: Implications for antiviral immunity and extension of lifespan

Geier, C., & Perl, A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102984 · Cited by 39 · see citing works

Turkish Journal of Hematology

(2026) · Turkish Journal of Hematology · doi:10.4274/tjh · Cited by 39 · see citing works

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

Pierson, S., Katz, L., Williams, R., Mumau, M. D., Gonzalez, M. V., Guzman, S., Rubenstein, A., Oromendia, A., Beineke, P., Fosså, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34873-7 · Cited by 29 · see citing works

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes

Pierson, S. K., Lim, M. S., Srkalović, G., Brandstadter, J. D., Bustamante, M. S., Shyamsundar, S., Mango, N., Lavery, C. L. M., Austin, B. P., Alapat, D. V., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010745 · Cited by 35 · see citing works

Grape Seed Proanthocyanidin Extract Ameliorates Cardiac Remodelling After Myocardial Infarction Through PI3K/AKT Pathway in Mice

Ruan, Y., Jin, Q., Zeng, J., Ren, F., Xie, Z.-Y., Ji, K., Wu, L., Wu, J., & Li, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585984 · Cited by 35 · see citing works

ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder

Pierson, S. K., Khor, J. S., Ziglar, J. A., Liu, A. Y., Floess, K., Napier, E., Gorzewski, A. M., Tamakloe, M.-A., Powers, V., Akhter, F., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100158 · Cited by 35 · see citing works

Emerging role of 18F-FDG PET/CT in Castleman disease: a review

Koa, B., Borja, A. J., Aly, M., Padmanabhan, S., Tran, J., Zhang, V., Rojulpote, C., Pierson, S. K., Tamakloe, M.-A., Khor, J. S., et al. (2021) · Insights into Imaging · doi:10.1186/s13244-021-00963-1 · Cited by 35 · see citing works

IgG4-related disease and idiopathic multicentric Castleman's disease: confusable immune-mediated disorders.

Sasaki, T., Akiyama, M., Kaneko, Y., & Takeuchi, T. (2021) · Rheumatology · doi:10.1093/rheumatology/keab634 · Cited by 24 · see citing works

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

Fajgenbaum, D. C., Wu, D., Goodman, A. M., Wong, R. S. M., Chadburn, A., Nasta, S. D., Srkalović, G., Mukherjee, S., Leitch, H. A., Jayanthan, R., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25992 · Cited by 33 · see citing works

Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL‐6/JAK inhibition: A pediatric case series

Lust, H., Gong, S., Remiker, A. S., & Rossoff, J. E. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29261 · Cited by 31 · see citing works

Candidate biomarkers for idiopathic multicentric Castleman disease

Sumiyoshi, R., Koga, T., & Kawakami, A. (2022) · Journal of Clinical and Experimental Hematopathology · doi:10.3960/jslrt.22010 · Cited by 28 · see citing works

Multicentric Castleman disease and the evolution of the concept

Zhou, T., Wang, H.-W., Pittaluga, S., & Jaffe, E. (2021) · Pathologica · doi:10.32074/1591-951x-351 · Cited by 22 · see citing works

Assessment of type I interferon signatures in undifferentiated inflammatory diseases: A Japanese multicenter experience

Miyamoto, T., Honda, Y., Izawa, K., Kanazawa, N., Kadowaki, S., Ohnishi, H., Fujimoto, M., Kambe, N., Kase, N., Shiba, T., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.905960 · Cited by 28 · see citing works

TAFRO syndrome: A severe manifestation of Sjogren's syndrome? A systematic review

Grange, L., Chalayer, É., Boutboul, D., Paul, S., Galicier, L., Gramont, B., & Killian, M. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103137 · Cited by 27 · see citing works

Remodeling of T-cell mitochondrial metabolism to treat autoimmune diseases

Lin, L., Ren, R., Xiong, Q., Zheng, C., Yang, B., & Wang, H. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103583 · Cited by 26 · see citing works

A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD

Zhang, L., Zhang, M., Cao, X., Zhou, D., Fajgenbaum, D. C., Dong, Y., & Li, J. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1999437 · Cited by 26 · see citing works

Sharing is caring: a call for a new era of rare disease research and development

Denton, N., Mulberg, A. E., Molloy, M., Charleston, S., Fajgenbaum, D. C., Marsh, E. D., & Howard, P. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02529-w · Cited by 25 · see citing works

Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis

Musiu, C., Caligola, S., Fiore, A., Lamolinara, A., Frusteri, C., Pizzo, F. D. D., Sanctis, F. D., Canè, S., Adamo, A., Hofer, F., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00866-0 · Cited by 24 · see citing works

Selenium and Taurine Combination Is Better Than Alone in Protecting Lipopolysaccharide‐Induced Mammary Inflammatory Lesions via Activating PI3K/Akt/mTOR Signaling Pathway by Scavenging Intracellular ROS

Liu, D., Lin, J., He, W., & Huang, K. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5048375 · Cited by 22 · see citing works

The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease

Horna, P., King, R. L., Jevremović, D., Fajgenbaum, D. C., & Dispenzieri, A. A. (2022) · Haematologica · doi:10.3324/haematol.2021.280370 · Cited by 21 · see citing works

Patient’s age and d-dimer levels predict the prognosis in patients with TAFRO syndrome

Kawabata, H., Fujimoto, S., Sakai, T., Yanagisawa, H., Kitawaki, T., Nara, K., Hagihara, M., Yamamoto, H., Tanimizu, M., Kato, C., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03159-x · Cited by 20 · see citing works

Identifying Key Genes and Functionally Enriched Pathways of Diverse Adipose Tissue Types in Cattle

Pan, C., Yang, C., Wang, S., & Ma, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.790690 · Cited by 18 · see citing works

Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease

Harada, T., Kikushige, Y., Miyamoto, T., Uno, K., Niiro, H., Kawakami, A., Koga, T., Akashi, K., & Yoshizaki, K. (2023) · Nature Communications · doi:10.1038/s41467-023-42718-0 · Cited by 19 · see citing works

Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with Bilateral Adrenal Hemorrhage in Two Caucasian Patients

Ducoux, G., Guerber, A., Durel, C., Asli, B., Fadlallah, J., & Hot, A. (2020) · American Journal of Case Reports · doi:10.12659/ajcr.919536 · Cited by 18 · see citing works

TAFRO syndrome: A disease that known is half cured

Chen, T., Feng, C., Zhang, X., & Zhou, J. (2022) · Hematological Oncology · doi:10.1002/hon.3075 · Cited by 17 · see citing works

Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease

Bustamante, M. S., Pierson, S. K., Ren, Y., Bagg, A., Brandstadter, J. D., Srkalović, G., Mango, N., Alapat, D. V., Lechowicz, M. J., Li, H., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.283603 · Cited by 17 · see citing works

Cytoplasmic RNA quality control failure engages mTORC1-mediated autoinflammatory disease

Yang, K., Han, J., Asada, M., Gill, J. G., Park, J. Y., Sathe, M., Gattineni, J., Wright, T., Wysocki, C., de la Morena, M. T., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci146176 · Cited by 16 · see citing works

SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics

Schneider, D. J., Lynch, S. A., Gelinas, A. D., Ostroff, R. M., Rohloff, J. C., Williams, P., Janjić, N., & Drolet, D. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00007-5 · Cited by 14 · see citing works

Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19

Gamarra-Morales, Y., Herrera‐Quintana, L., Molina‐López, J., Vázquez‐Lorente, H., Machado-Casas, J. F., Castaño-Pérez, J., Pérez-Villares, J. M., & Planells, E. (2023) · Nutrients · doi:10.3390/nu15092235 · Cited by 14 · see citing works

Inflammatory diseases in hematology: a review

Henrie, R., Cherniawsky, H. M., Marcon, K. M., Zhao, E. J., Marinkovic, A., Pourshahnazari, P., Parkin, S., & Chen, L. Y. C. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00356.2021 · Cited by 16 · see citing works

The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman‐like lymphadenopathies: A 20‐year retrospective analysis of clinical and pathological features

Pelliccia, S., Rogges, E., Cardoni, A., Lopez, G., Conte, E., Faccini, A. L., Vito, R. D., Girardi, K., Bianchi, A., Annibali, O., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19171 · Cited by 14 · see citing works

Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO

Srkalović, G., Nijim, S., Srkalovic, M. B., & Fajgenbaum, D. C. (2024) · Biomedicines · doi:10.3390/biomedicines12061328 · Cited by 14 · see citing works

Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease

Koga, T., Hagimori, N., Takemori, S., Morimoto, S., Sumiyoshi, R., Shimizu, T., Hosogaya, N., Fukushima, C., Yamamoto, H., & Kawakami, A. (2020) · Medicine · doi:10.1097/md.0000000000020710 · Cited by 13 · see citing works

Unraveling TAFRO Syndrome: An In-Depth Look at the Pathophysiology, Management, and Future Perspectives

Caballero, J. C., Conejero, N., Solán, L., de la Pinta, F. J. D., Córdoba, R., & López‐García, A. (2024) · Biomedicines · doi:10.3390/biomedicines12051076 · Cited by 12 · see citing works

Increased mTORC2 pathway activation in lymph nodes of iMCD‐TAFRO

Phillips, A., Kakkis, J. J., Tsao, P., Pierson, S. K., & Fajgenbaum, D. C. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17251 · Cited by 11 · see citing works

Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study

Liu, Y., Gao, Y., Zhao, H., Zhang, M., Duan, M., Li, J., & Zhang, L. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05783-z · Cited by 12 · see citing works

Independent and synergistic effects of extreme heat and NO2 pollution on diabetic nephropathy in a type II diabetes mouse model

Qiao, Z., Feng, X., Sun, W., Wang, F., & Lu, C. (2025) · Environmental Pollution · doi:10.1016/j.envpol.2025.126321 · Cited by 11 · see citing works

A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus

Sumiyoshi, R., Koga, T., Furukawa, K., Umeda, M., Yamamoto, K., Mori, R., & Kawakami, A. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108887 · Cited by 11 · see citing works

Targeting the mTOR pathway in idiopathic multicentric Castleman disease

Stern, R. M., & Berliner, N. (2019) · Journal of Clinical Investigation · doi:10.1172/jci131332 · Cited by 10 · see citing works

Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy

Bayram, E., Pehlivan, U. A., Fajgenbaum, D. C., & Paydaş, S. (2022) · American Journal of Hematology · doi:10.1002/ajh.26783 · Cited by 9 · see citing works

T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms

Fraticelli, S., Lucioni, M., Neri, G., Marchiori, D., Cristinelli, C., Merli, M., Monaco, R., Borra, T., Lazzaro, A., Uccella, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097813 · Cited by 9 · see citing works

Biomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome

Sumiyoshi, R., Koga, T., & Kawakami, A. (2024) · Biomedicines · doi:10.3390/biomedicines12061141 · Cited by 10 · see citing works

[Castleman disease].

Meignin, V., Calvani, J., & Oksenhendler, E. (2022) · Annales de Pathologie · doi:10.1016/j.annpat.2022.07.013 · Cited by 9 · see citing works

Long-term clinicopathological characteristics of TAFRO syndrome and its relapse: a case series study

Yoshimura, Y., Mizuno, H., Ikuma, D., Yamanouchi, M., Sekine, A., Suwabe, T., Oba, Y., Kurihara, S., Sugimoto, H., Inoue, N., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae110 · Cited by 8 · see citing works

Pathophysiology, Treatment, and Prognosis of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome: A Review

Kakutani, T., Kamada, R., & Tamai, Y. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46100668 · Cited by 6 · see citing works

Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor

Evans, J. F., Rue, R. W., Mukhitov, A. R., Obraztsova, K., Smith, C. J., & Krymskaya, V. P. (2019) · Biomolecules · doi:10.3390/biom10010028 · Cited by 7 · see citing works

How we manage idiopathic multicentric Castleman disease.

Brandstadter, J. D., & Fajgenbaum, D. C. (2022) · PubMed · Cited by 8 · see citing works

Castleman Disease

Chen, L., & Fajgenbaum, D. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-23488-0_51 · Cited by 9 · see citing works

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

Yin, X., Liu, Y., Ding, S., Ge, J., Yang, M., Wang, Z., Lv, Z., Luo, X., Ma, L., Yu, W., et al. (2025) · Blood · doi:10.1182/blood.2024027689 · Cited by 7 · see citing works

Room for improvement in clinical trials for rare diseases

Musters, A., & Tas, S. W. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0376-6 · Cited by 7 · see citing works

Protective effect of rivastigmine against lung injury in acute pancreatitis model in rats via Hsp 70/IL6/ NF-κB signaling cascade

Kamel, M. Y., Attia, J. Z., Ahmed, S. M., Saeed, Z. H., Welson, N. N., & Abdelzaher, W. Y. (2023) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320231222804 · Cited by 7 · see citing works

An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease

Koga, T., Takemori, S., Hagimori, N., Morimoto, S., Sumiyoshi, R., Shimizu, T., Hosogaya, N., Fukushima, C., Yamamoto, H., & Kawakami, A. (2020) · Medicine · doi:10.1097/md.0000000000023291 · Cited by 7 · see citing works

The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry

Fajgenbaum, D. C., Pierson, S. K., Kanhai, K. J. K., Bagg, A., Alapat, D. V., Lim, M. S., Lechowicz, M. J., Srkalović, G., Uldrick, T. S., van Rhee, F., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18214 · Cited by 6 · see citing works

Efficacy of High‐Dose Intravenous Anakinra in Pediatric TAFRO Syndrome: Report of Two Cases and Literature Review

Palmeri, S., Ferro, J., Natoli, V., Matucci‐Cerinic, C., Papa, R., Rosina, S., Sorrentino, S., Volpi, S., Vellone, V. G., Gattorno, M., et al. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31759 · Cited by 6 · see citing works

Clinical features and treatment outcomes of Castleman disease in children: a retrospective cohort in China

Hu, S., Li, Z., Wang, H., Chen, L., Ma, Y., Zhu, X., Li, J., Dong, R., Yao, W., Dong, C., et al. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-05235-2 · Cited by 7 · see citing works

Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions

Fang, X., Sun, Z., Xu-Monette, Z. Y., & Young, K. H. (2020) · The Oncologist · doi:10.1002/onco.13605 · Cited by 6 · see citing works

Differential expression of circular RNAs in interleukin 6-promoted osteogenic differentiation of human stem cells from apical papilla

Hu, G., Wu, L., Xue, K., Han, H., Sun, Y., Gan, K., Zhu, J., Shi, Q., & Du, T. (2023) · Clinical Oral Investigations · doi:10.1007/s00784-023-05366-8 · Cited by 5 · see citing works

Meprin β activity modulates cellular proliferation via trans-signaling IL-6-mediated AKT/ERK pathway in IR-induced kidney injury

Abousaad, S., Ahmed, F., Abouzeid, A., Adhiambo, C., & Ongeri, E. M. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04224-x · Cited by 5 · see citing works

TAFRO Syndrome and COVID-19

Tane, M., Kosako, H., Sonoki, T., & Hosoi, H. (2024) · Biomedicines · doi:10.3390/biomedicines12061287 · Cited by 6 · see citing works

Hemophagocytic Lymphohistiocytosis and Other Cytokine Storm Syndromes in Adults

Goubran, M., & Chen, L. Y. C. (2025) · Canadian Hematology Today · doi:10.58931/cht.2025.4166 · Cited by 5 · see citing works

Glycogen synthase kinase 3β/CCR6‐positive bone marrow cells correlate with disease activity in multicentric Castleman disease‐TAFRO

Abe, N., Kono, M., Kono, M., Ohnishi, N., Sato, T., Tarumi, M., Yoshimura, M., Sato, T., Karino, K., Shimizu, Y., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17993 · Cited by 6 · see citing works

Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report

Gao, Y., Duan, M., Li, J., & Zhang, L. (2024) · British Journal of Haematology · doi:10.1111/bjh.19596 · Cited by 5 · see citing works

Glioblastoma cell-induced immunosuppression causing chemoresistance

Sordillo, P., & Sordillo, L. A. (2021) · Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies · doi:10.1016/b978-0-12-821567-8.00008-7 · Cited by 6 · see citing works

Thrombocytopenia, anasarca, and severe inflammation

Montazeripouragha, A., Campbell, C. M., Russell, J. A., Medvedev, N., Owen, D. R., Harris, A. C., Donnellan, F. K., McCormick, I., Fajgenbaum, D. C., & Chen, L. Y. C. (2022) · American Journal of Hematology · doi:10.1002/ajh.26651 · Cited by 5 · see citing works

The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

Seervai, R. N. H., Friske, S. K., Chu, E. Y., Phillips, R. M., Nelson, K. C., Huen, A., Cho, W. C., Aung, P. P., Torres-Cabala, C. A., Prieto, V. G., et al. (2022) · Journal of Cutaneous Pathology · doi:10.1111/cup.14327 · Cited by 6 · see citing works

Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study

Nishimura, Y., Habermann, T. M., Gertz, M. A., Porrata, L., Johnston, P. B., Lin, Y., Buadi, F. K., Dingli, D., Wang, Y., Leung, N., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025018324 · Cited by 4 · see citing works

Deciphering the Iron Metabolism and Ferroptosis in Diabetic Wound Healing

Feng, Y.-S., Cao, Y.-C., Ouyang, Y., Wang, W.-X., & Feng, S.-L. (2025) · Current Diabetes Reviews · doi:10.2174/0115733998352547250107065356 · Cited by 4 · see citing works

The Involvement of PI3K–Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease–Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified Subtypes

Haratake, T., Nishimura, M. F., Nishikori, A., Gonzalez, M. V., Ennishi, D., Lai, Y. C., Ochi, S., Tsunoda, M., Fajgenbaum, D. C., van Rhee, F., et al. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100782 · Cited by 4 · see citing works

Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease: A Consensus-based Position Paper From an ad hoc Expert Panel

Zinzani, P. L., Paulli, M., Arcaini, L., Della‐Torre, E., Ferrero, S., Figuera, A., Frigeri, F., Martelli, M., Sabattini, E., Scarpa, R., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000891 · Cited by 4 · see citing works

Exploring the role of insulin-like growth factor binding protein-1 in identifying idiopathic multicentric Castleman's disease types: Implications for the mTOR signaling pathway

Sumiyoshi, R., Koga, T., Fukui, S., Furukawa, K., Momoki, M., Ichinose, K., Yano, S., & Kawakami, A. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109798 · Cited by 5 · see citing works

Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease

Nishikori, A., Nishimura, M. F., Tomida, S., Chijimatsu, R., Ueta, H., Lai, Y. C., Kawahara, Y., Takeda, Y., Ochi, S., Haratake, T., et al. (2024) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.24061 · Cited by 4 · see citing works

Intracranial Hemorrhage in a Patient with TAFRO Syndrome Treated with Cyclosporine A and Rituximab

Akagi, Y., Kato, T., Yamashita, Y., Hosoi, H., Murata, S., Yamamoto, S., Warigaya, K., Nakao, T., Murata, S., Sonoki, T., et al. (2021) · Medicina · doi:10.3390/medicina57090971 · Cited by 4 · see citing works

Siltuximab Monotherapy in Tafro Syndrome: A Case Report and Review of the Literature

Cordero, L., Aguilar-Rodríguez, F., Sandino, J., Alonso, M., & Gutiérrez, E. (2023) · Journal of Nephrology · doi:10.1007/s40620-022-01517-4 · Cited by 4 · see citing works

Immunology and targeted therapy in Castleman disease

Tsunoda, S., Harada, T., Kikushige, Y., Kishimoto, T., & Yoshizaki, K. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2357689 · Cited by 4 · see citing works

The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease

Alnoor, F., Spies, N. C., Kumar, J., Samghabadi, P., Silva, O., Luo, M., Chisholm, K. M., Zhang, J., Rangel, A. E., Ng, D. P., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70039 · Cited by 3 · see citing works

A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease

Zhang, L., Gao, Y., Li, S., Zhao, H., Zhang, M., Yu, Y.-Y., Liu, Y., & Li, J. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03747-7 · Cited by 3 · see citing works

mTOR signaling as a driver of Castleman disease

Colgan, J. D. (2020) · Blood · doi:10.1182/blood.2020005361 · Cited by 3 · see citing works

Targeting the mTOR pathway in idiopathic multicentric Castleman disease

Stern, R. M., & Berliner, N. (2019) · Journal of Clinical Investigation · doi:10.1172/jci131332 · Cited by 10 · see citing works

Increased mTOR activation in idiopathic multicentric Castleman disease

Arenas, D., Floess, K., Kobrin, D. M., Srkalovic, M. B., Pierson, S. K., Martínez, D., & Fajgenbaum, D. C. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.502 · Cited by 2 · see citing works

P-122: Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO

Phillips, A., Kakkis, J. J., Pierson, S. K., & Fajgenbaum, D. C. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(21)02249-7

Candidate biomarkers for idiopathic multicentric Castleman disease

Sumiyoshi, R., Koga, T., & Kawakami, A. (2022) · Journal of Clinical and Experimental Hematopathology · doi:10.3960/jslrt.22010 · Cited by 28 · see citing works

Increased mTORC2 pathway activation in lymph nodes of iMCD‐TAFRO

Phillips, A., Kakkis, J. J., Tsao, P., Pierson, S. K., & Fajgenbaum, D. C. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17251 · Cited by 11 · see citing works